<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="212">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158387</url>
  </required_header>
  <id_info>
    <org_study_id>D9180C00004</org_study_id>
    <secondary_id>2021-003771-34</secondary_id>
    <nct_id>NCT05158387</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MEDI3506 in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.</brief_title>
  <acronym>TITANIA</acronym>
  <official_title>A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (TITANIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase III study is to evaluate the efficacy and safety of MEDI3506 Dose 1&#xD;
      and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and&#xD;
      history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months.&#xD;
      Participants should be receiving optimised treatment with maintenance inhaled therapy&#xD;
      (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not indicated or contraindicated)&#xD;
      in stable doses throughout at least 3 months prior to enrolment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 7, 2022</start_date>
  <completion_date type="Anticipated">August 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 5, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>unblinded administrator/pharmacist</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>The primary endpoint will be assessed first in the primary population (former smokers with symptomatic COPD and a history of exacerbations, on optimised treatment with maintenance inhaled therapy [triple therapy, or dual therapy if triple is not indicated or contraindicated]) and then assessed in the overall population of participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of moderate to severe COPD exacerbations in former or current smokers.</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>The annualized rate will be assessed in the overall population of participants including current and former smokers with symptomatic COPD and history of exacerbations, on optimised treatment with maintenance inhaled therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first moderate to severe COPD exacerbation in former smokers.</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>To explore the extent to which treatment with each dose of MEDI3506 delays the time to first exacerbation compared with placebo in former smokers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in pre-BD, pre-dose trough FEV1 (mL) in former smokers.</measure>
    <time_frame>US - week 52; Ex-US - over 52 weeks</time_frame>
    <description>Change from baseline in pre-bronchodilator, pre dose trough FEV1 (mL) in former smokers. US and EX-US testing approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders achieving MCID in E-RS:COPD total score in former smokers .</measure>
    <time_frame>Week 52</time_frame>
    <description>Responder analyses for E-RS:COPD total score at Week 52 based upon a ≥ 2 point improvement (decrease) from baseline in former smokers. US testing approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in E-RS:COPD total score in former smokers.</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>Difference in mean change in E-RS:COPD total score from baseline in former smokers. Ex-US testing approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders achieving MCID in SGRQ total score in former smokers.</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants with a decrease in SGRQ total score of ≥ 4 points from baseline in former smokers. US testing approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in SGRQ total score from in former smokers.</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>Difference in mean change from baseline in SGRQ total score in former smokers. Ex-US testing approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first severe COPD exacerbation in former smokers.</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>To evaluate hazard ratio of first severe COPD exacerbation in former smokers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of severe COPD exacerbations in former smokers.</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>The rate ratio of severe COPD exacerbations will be assessed in former smokers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CAT total score.</measure>
    <time_frame>Week 52</time_frame>
    <description>Analyses of change from baseline in CAT total score in former smokers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a decrease in CAT total score in former smokers.</measure>
    <time_frame>Week 52</time_frame>
    <description>Proportion of participants achieving MCID in CAT total score, a decrease in CAT total score of ≥ 2 points from baseline in former smokers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants having ≥ 1 healthcare resource utilization type in former smokers.</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>Proportion of participants having ≥ 1 healthcare resource utilization type in former smokers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of healthcare resource utilization in former smokers.</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>Annualized rate of healthcare resource utilization in former smokers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in mean number of puffs per day in rescue use in former smokers.</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>Difference in mean number of puffs per day from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough serum concentrations of MEDI3506.</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>Pharmacokinetics: concentrations of MEDI3506 in trough serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-drug antibodies.</measure>
    <time_frame>over 60 weeks</time_frame>
    <description>Immunogenicity: presence of MEDI3506 anti-drug antibodies in blood serum.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1272</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>MEDI3506 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing subcutaneously MEDI3506 Dose 1 and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI3506 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing subcutaneously MEDI3506 Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosing subcutaneously with equivalent volume to MEDI3506</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI3506</intervention_name>
    <description>Administered subcutaneously MEDI3506 Dose 1 and placebo through Week 52, or dosing with MEDI3506 Dose 2 through Week 52.</description>
    <arm_group_label>MEDI3506 Dose 1</arm_group_label>
    <arm_group_label>MEDI3506 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered subcutaneously, equivalent volume to MEDI3506.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant must be ≥ 40 years of age and capable of giving signed informed consent.&#xD;
&#xD;
          2. Documented diagnosis of COPD for at least one year prior to enrolment.&#xD;
&#xD;
          3. Post BD FEV1/FVC &lt; 0.70 and post-BD FEV1 &gt;20% of predicted normal value.&#xD;
&#xD;
          4. Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months&#xD;
             prior to enrolment.&#xD;
&#xD;
          5. Documented optimized inhaled dual or triple therapy at a stable dose for at least 3&#xD;
             months prior to enrolment.&#xD;
&#xD;
          6. Smoking history of ≥ 10 pack-years.&#xD;
&#xD;
          7. CAT total score ≥10, and each of the phlegm (sputum) and cough items ≥ 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically important pulmonary disease other than COPD.&#xD;
&#xD;
          2. Radiological findings suggestive of a respiratory disease other than COPD that is&#xD;
             contributing to the participant's respiratory symptoms.&#xD;
&#xD;
          3. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap.&#xD;
             Childhood history of asthma is allowed and defined as asthma diagnosed and resolved&#xD;
             before the age of 18.&#xD;
&#xD;
          4. Any unstable disorder, including, but not limited to, cardiovascular,&#xD;
             gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious,&#xD;
             endocrine, metabolic, haematological, psychiatric disorder, major physical and/or&#xD;
             cognitive impairment that could affect safety, study findings or participants ability&#xD;
             to complete the study.&#xD;
&#xD;
          5. COPD exacerbation, within 2 weeks prior to randomization, that was treated with&#xD;
             systemic corticosteroids and/or antibiotics, and/or led to hospitalization.&#xD;
&#xD;
          6. Active significant infection within the 4 weeks prior to randomization, pneumonia&#xD;
             within 6 weeks prior to randomization, or medical condition that predisposes the&#xD;
             participant to infection.&#xD;
&#xD;
          7. Suspicion of, or confirmed, ongoing SARS-CoV-2 infection.&#xD;
&#xD;
          8. Significant COVID-19 illness within the 6 months prior to enrolment.&#xD;
&#xD;
          9. Unstable cardiovascular disorder.&#xD;
&#xD;
         10. Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular&#xD;
             failure.&#xD;
&#xD;
         11. History of known immunodeficiency disorder, including a positive test for HIV-1 or HIV&#xD;
             2.&#xD;
&#xD;
         12. History of positive test or treatment for hepatitis B or hepatitis C.&#xD;
&#xD;
         13. Evidence of active liver disease, including jaundice during screening.&#xD;
&#xD;
         14. Malignancy, current or within the past 5 years, except for adequately treated&#xD;
             non-invasive basal cell and squamous cell carcinoma of the skin and cervical&#xD;
             carcinoma-in-situ treated with apparent success more than one year prior to enrolment.&#xD;
             Suspected malignancy or undefined neoplasms.&#xD;
&#xD;
         15. Participants who have evidence of active TB.&#xD;
&#xD;
         16. Participants that have previously received MEDI3506.&#xD;
&#xD;
         17. Any clinically significant abnormal findings in physical examination, vital signs,&#xD;
             ECG, or laboratory testing during the screening period, which in the opinion of the&#xD;
             investigator may put the participant at risk because of their participation in the&#xD;
             study, or may influence the results of the study, or the participant's ability to&#xD;
             complete the entire duration of the study.&#xD;
&#xD;
         18. Active vaping of any products within the 6 months prior to randomization and during&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Georgetown</city>
        <state>Kentucky</state>
        <zip>40324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankstown</city>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spearwood</city>
        <zip>6163</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bento Gonçalves</city>
        <zip>95700-084</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blumenau</city>
        <zip>89030-101</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Botucatu</city>
        <zip>18618-686</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasilia</city>
        <zip>71681-603</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <zip>80730-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>9002-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22061-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Bernardo do Campo</city>
        <zip>09750-420</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01327-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sorocaba</city>
        <zip>18040-425</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>01409-02</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>7500692</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>8241479</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Talca</city>
        <zip>3465584</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Viña del Mar</city>
        <zip>2520997</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <zip>80007</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ibague</city>
        <zip>730006</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medellin</city>
        <zip>050034</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rionegro</city>
        <zip>54040</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halle</city>
        <zip>6108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Köln</city>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München-Pasing</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peine</city>
        <zip>31224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>15046</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>L18</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 21</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piura</city>
        <zip>20001</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo City</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elbląg</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-648</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Opole</city>
        <zip>45-401</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrowiec Świętokrzyski</city>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>61-578</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-205</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>50159</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <zip>700304</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izhevsk</city>
        <zip>426035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>107150</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Penza</city>
        <zip>440067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perm</city>
        <zip>614000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bang Kra So</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hat Yai</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muang,</city>
        <zip>55000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 7EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corby</city>
        <zip>NN17 2UR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corby</city>
        <zip>NN18 9EZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shipley</city>
        <zip>BD18 3SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wokingham</city>
        <zip>RG40 1XS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

